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Abstract: Glycaemic control has been shown to improve outcome in critically ill patients, but hard to 
achieve in a safe and effective manner. This paper presents the preliminary results of 8 patients controlled 
at the University Hospital of Liège under STAR-Liège, an insulin-only version of the model-based STAR 
glycaemic controller framework. Clinical data is compared with virtual trial simulations of the glycaemic 
control outcomes for the STAR-Liège protocol, and with the standard of care protocol of this intensive 
care unit, to assess safety, performance, and compliance of the new protocol. 
Results show 78% of clinical blood glucose measurements in target band. Only 3% of blood glucose 
measurements were below 4.4 mmol/L (79 mg/dL), with only 1% mild hypoglycaemia and no severe 
hypoglycaemia. These results are similar to simulation of the protocol, but slightly higher workload is 
observed clinically due to nursing choice. Compared to standard protocol virtual trial simulations, STAR-
Liège achieved tighter and less variable control with similar safety, and less percentage time in higher 
blood glucose levels. Clinically, 14% of insulin intervention were increased or decreased from 
recommendation with median [IQR] change of 1 [1, 2] or -2 [-3, -2] U/hr respectively. 
Clinical and simulation results show STAR-Liège better controls glycaemia to lower ranges compared to 
the standard protocol, while ensuring safety. Lower time in higher blood glucose ranges potentially 
improves patient outcomes. Compliance analysis shows potential nurse fears in protocol changes and 
different insulin dosing. These results are encouraging for the continuation of the clinical trial realised in 
this medical intensive care unit and its extension to insulin and nutrition control. 
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1. INTRODUCTION 
Stress-induced hyperglycaemia is a common complication in 
critically ill patients (McCowen et al., 2001). Abnormal and 
highly variable blood sugar (BG) levels are associated with 
increased mortality and morbidity (Bagshaw et al., 2009; 
Capes et al., 2000; Egi et al., 2006; Egi et al., 2010; Krinsley, 
2008). Many studies have shown beneficial outcomes using 
insulin therapy for these patients, reducing mortality, 
morbidity, length of stay, and workload (Chase et al., 2010a; 
Krinsley, 2004, 2005; Reed et al., 2007; Van den Berghe et 
al., 2001; Van den Berghe et al., 2003). However, others 
have shown glycaemic control (GC) hard to reproduce safely, 
with significantly increased risk of hypoglycaemia for no 
reductions in mortality (Brunkhorst et al., 2008; Finfer et al., 
2009; Finfer et al., 2012; Preiser et al., 2009). 
The debate over whether tight glycaemic control is beneficial 
or harmful for intensive care unit (ICU) patients (Marik, 
2016; Preiser et al., 2016) is thus legitimate. A recent study 
showed no difference in insulin sensitivity and variability 
between survivors and non-survivors, implying that the 
association between glycaemic outcomes and mortality is a 
function of GC achieved and not patient condition 
(Uyttendaele et al., 2017). Thus, good GC protocol design 
can be essential for patient outcome. Hence, insulin therapy 
needs to be safe and effective for all patients, offering a ‘one 
method fits all’ solution, and be repeatable across ICUs 
(Stewart et al., 2016) before any potential beneficial impact 
can be assessed (Chase et al., 2017). 
STAR is a GC framework using physiological and stochastic 
models to dose insulin and nutrition (Evans et al., 2012; Fisk 
et al., 2012). STAR uses a risk-based dosing approach, 
accounting for intra- and inter- patient variability (Lin et al., 
2008). Model-based insulin sensitivity (SI) is determined 
using clinical data, and its likely future variability is assessed 
using a stochastic model built on population data (Lin et al., 
2006; Lin, et al., 2008; Lin et al., 2011). This risk-based 
forward prediction of SI allows STAR to adjust treatment so 
the resulting predicted BG outcome best (and safely) overlaps 
a clinically chosen target band. STAR has shown safe,  
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effective control in Christchurch, New Zealand, and Gyula, 
Hungary, where it is the standard of care (Stewart, et al., 
2016). STAR is a user-friendly software, and easily adaptable 
to different ICU practices. 
This paper presents intermediate clinical trial results of a 
modified, insulin-only version of STAR (STAR-Liège) at the 
University Hospital of Liège (CHU), Belgium. This clinical 
trial assesses the performance of STAR and the impact of this 
new model-based solution on nurse workload. This trial is 
realised over two major phases of 20 patients each. During 
the first phase, only insulin intervention will be suggested, 
while nutrition is left to clinician discretion. The second 
phase will control both nutrition and insulin inputs. 
2. METHODS 
2.1 STAR-Liège protocol 
STAR-Liège is an insulin-only version of STAR (Evans, et 
al., 2012; Fisk, et al., 2012) with starting criteria of 2 
successive BG > 8.0 mmol/L (145 mg/dL). Insulin is 
administered continuously through arterial IV catheter. 
Increments of maximum 2 U/hr of insulin are allowed, and 
the maximum rate is 9 U/hr. STAR-Liège targets 4.4-8.0 
mmol/L (79 – 145 mg/dL). STAR-Liège stopping criteria are 
defined as stable BG over the last 6 hours period during 
which low insulin was given (≤ 2U/hr), either for clinical 
reasons, or after 72 hours on the protocol. The University 
Hospital of Liège Ethics Committee approved this trial and 
the use of this data. 
Using clinical data, model-based SI is determined from a 
clinically validated physiological model (Lin, et al., 2011). SI 
characterises the patient-specific metabolic response to 
insulin. Based on this current SI value, the stochastic model, 
built on population data, is used to determine the distribution 
of future SI, thus accounting for future metabolic variability. 
The 5th and 95th percentile of likely future SI are used to 
determine the corresponding 95th and 5th percentiles of future 
BG outcomes, for a given intervention. STAR-Liège thus 
determines the best insulin intervention that best overlaps the 
clinically chosen target band, ensuring a maximum of 5% 
risks for BG < 4.4 mmol/L (79 mg/dL). STAR-Liège offers 1 
to 3 hourly treatment options based on patient stability and 
treatment risk profiles. 
2.2 Standard protocol 
The GC standard of care in this ICU is a table-based sliding 
scale protocol, using the current BG and previous insulin rate 
to adjust insulin intervention. This protocol targets the 5.6-
8.3 mmol/L (100-150 mg/dL) band, with a maximum insulin 
rate of 50 U/hr. Starting criteria is BG > 10.0 mmol/L (180 
mg/dL). Measurements are taken 4-hourly if BG is stabilised 
with two consecutive BG measurements between 5.6 and 
10.0 mmol/L (100 and 180 mg/dL). If BG is not stable and/or 
if insulin rate was changed, BG is measured hourly. Full 
details are presented in (Penning et al., 2014). 
2.3 Protocol comparisons 
This study analyses and compares the GC outcomes from the 
first 8 patients included in the STAR-Liège trial, and 
simulated GC outcomes from virtual simulations of the 
STAR-Liège protocol and the standard of care protocol 
currently used. These virtual trials are simulated based on 
virtual patients characterised by their model-based SI 
profiles, which were created from clinical data. Real data and 
simulation data can be compared to assess compliance to the 
original protocol. Nutrition profiles in simulations are based 
on clinical data. The generalisability across different cohorts 
and ICUs of such virtual trials has been validated in (Chase et 
al., 2010b; Dickson et al., 2017). Additionally, retrospective 
clinical glycaemic control data from 20 patients was collected 
for the Liège sliding scale protocol for comparison and 
assessment of clinical compliance. These latter patients were 
presented elsewhere (Dickson, et al., 2017). Clinical outcome 
is not analysed in this study. 
2.4 Analyses 
This analysis focuses on the safety and performance of 
different GC protocols. Performance is assessed using the 
percentage of hourly resampled BG measurements in the 4.4-
8.0 mmol/L (79-145 mg/dL) target band and the per-patient 
median [IQR] BG. Safety is evaluated by the percentage BG 
with mild hypoglycaemia (BG < 4.0 mmol/L or 79 mg/dL), 
or severe hypoglycaemia (BG < 2.2 mmol/L or 40 mg/dL). 
BG data is resampled hourly to allow fair comparison across 
different measurement intervals. 
Clinical compliance is assessed for each protocol. 
Compliance is assessed as the number of unchanged insulin 
interventions from the original recommendation. Delays in 
insulin delivery of up to 15 minutes are not considered non-
compliant as long as the rate matches the recommendation. 
For the STAR-Liège protocol, the nurse selected treatment is 
compared with the treatment option with the maximum 
measurement interval available. 
In summary, this study compares the safety, performance, 
and compliance across: 
 Clinical GC data from 8 patients treated with the 
STAR-Liège protocol 
 Virtual trial simulations of the STAR-Liège protocol 
 Virtual trial simulations of the standard protocol 
 Retrospective clinical GC data from 20 patients 
treated with the standard protocol. 
3. RESULTS 
Clinical and simulation results are summarised in Table 1 for 
each protocol. Resampled BG and insulin rate cumulative 
distribution functions (CDFs) are shown in Figure 1. The 
evolution of BG traces over time for the 8 patients are also 
shown in Figure 2. 




     
 
3.1 STAR-Liège clinical trial results vs. virtual trials 
Clinical data shows very good performance with 78% of BG 
measurements within 4.4-8.0 mmol/L target band and a 
median [IQR] BG of 6.5 [5.8, 7.5]. Only 3% of BG were 
below the target band, with 1% BG < 4.0 mmol/L and no 
severe hypoglycaemia (0% BG < 2.2 mmol/L). 
Table 1 – Clinical and simulation results summary for 
performance, safety and compliance protocol comparison. 
BG stats are calculated from hourly resampled BG as 
measurement interval can differ from treatment to 
treatment. 
 STAR-Liège Standard Protocol 
 Clinical Sim. Sim. 
Retro. 
Clinical 
# Patients 8 20 





































% BG in 4.4-
8.0 mmol/L 
78 80 69 55 
% BG in 5.6-
8.3 mmol/L 
60.8 58 64 54 
% BG in 8.0-
10.0 mmol/L 
9 8 20 31 
% BG > 10.0 
mmol/L 
11 9 9 12 
% BG < 4.4 
mmol/L 
2 2 2 1 
% BG < 4.0 
mmol/L 
1 1 1 1 
% BG < 2.2 
mmol/L 




86 100 100 N/A 
Max. option 
chosen (%) 
86 100 100 N/A 









































Figure 1 – Cohort resampled BG and insulin rate CDFs 
comparison between simulations and real clinical data. 
 

















Figure 2 – Real BG evolution traces over time for the first 8 
patients treated under STAR-Liège protocol. Dashed lines 
show the target 4.4-8.0 mmol/L range. 
 
Compared to simulation, both safety and performance were 
similar. Slightly higher % BG in higher bands is observed 
(shift to the right of the CDF, 20% vs. 17% BG > 8.0 
mmol/L), explained by the overall lower median [IQR] 
insulin administered clinically (shift to the left of the CDF, 
2.0 [1.0, 5.5] vs. 2.5 [1.5, 6.5] U/hr median [IQR] insulin). 
The average number of measurements per day is higher 
clinically than simulated (16 vs. 14), and this increased 
workload is explained by 14% of actual treatment option 
selecting lower than the maximum measurement interval 
offered. Finally, 14% of insulin interventions were non-




     
 
compliant to protocol as insulin dose was changed from the 
original recommendation. Where treatments were non-
compliant to recommendations, 17 (47%) involved a median 
[IQR] reduction in insulin rate of -2 [-3, -2] U/hr, and 19 
(53%) involved a median [IQR] increase in insulin rate of 1 
[1, 2] U/hr. From data observation, insulin rate reduction 
often occurred when BG was close to target band limits at 
relatively high insulin rates (either when BG was decreasing 
and approaching the upper target band limit, or when BG was 
close to the lower target band limit). In contrast, 
modifications increasing insulin rate often occurred when 
STAR suggested important lowering in insulin 
administration, whereas nurses tended to dislike decreasing 
insulin rate too quickly. In general, this behaviour reflects a 
more dynamic dosing by STAR than nurses were used to, 
affecting compliance (Chase et al., 2008). It is important to 
note that giving higher insulin rates than recommended 
results in increased risk of hypoglycaemia (>5%) predicted 
by the controller (Evans, et al., 2012). Nutrition rates are 
equal as expected since simulations are based on clinical 
nutrition data.  
3.2 STAR-Liège protocol vs. standard protocol simulations 
Simulation results show the STAR-Liège protocol achieved 
tighter and less variable control (6.2 [5.6, 7.2] vs. 7.1 [6.1, 
8.2] mmol/L median [IQR] BG) than the sliding scale 
protocol without compromising safety. In Figure 1, the 
STAR-Liège BG CDF (green) is located to the left of the 
Standard protocol BG CDF (blue), and is more vertical and 
thus less variable. The % BG higher than 8.0 mmol/L is 
much lower for STAR-Liège (17% vs. 29%). However, 
STAR-Liège workload is greater (14 vs. 11 measurements 
per day), despite broadly similar insulin dosing (Figure 1). 
Note that the number of simulated hours difference between 
the protocols is due to when the last measurements within 
available data occurred, leading to last 1-2 hours being 
trimmed. 
3.3 Standard protocol retrospective data 
Although the reported metrics are not based on the same 
underlying cohort, this comparison is interesting for 
compliance assessment and overall protocol behaviour 
analysis. As shown in Table 1, median [IQR] BG is higher 
for the retrospective data (7.7 [6.5, 8.9] vs. 7.1 [6.1, 8.2] 
mmol/L) then simulations of the standard protocol, and the % 
BG > 8.0 mmol/L is higher, with lower insulin given (2.5 
[2.0, 3.0] vs. 3.0 [0.0, 6.0] U/hr). The very high percentage 
(40%) of hours without insulin in the simulation of the 
standard protocol (Figure 1) is explained by the different 
starting inclusion criteria (BG > 8.0 for STAR and BG > 10.0 
for standard protocol). In terms of performance, the 
simulation achieved 64% BG in the target band (5.6-8.3 
mmol/L) whereas 54% was achieved clinically. The average 
measurements/day is much lower at 7 measures/day. 
Simulations on this specific cohort of 20 patients have been 
previously published elsewhere (Dickson, et al., 2017), 
showing an important lack of compliance to the protocol in 
terms expected average measurement per day (7 vs. 11) and 
important modifications in insulin intervention, having direct 
impact on both protocol performance and safety. 
Interestingly, much higher nutrition rates are observed in this 
retrospective cohort compared to what have been given to  
STAR-Liège patients (9.8 [8.6, 11.5] vs. 7.8 [5.6, 9.0]), also 
impacting the higher % BG > 8.0 mmol/L. 
 
4. DISCUSSION 
These preliminary results from the STAR-Liège clinical trial 
are encouraging. Performance of STAR-Liège is similar to 
previous published performance of the original STAR 
protocol (Stewart, et al., 2016), despite modulating only 
insulin. As reported in Table 1, 14% of recommended insulin 
treatments were changed, typically reflecting a potential fear 
of too aggressive treatment or more dynamic changes in 
dosing than typically used, as nurses need time to learn and 
completely adapt to this new model-based solution. This 
issue can be explained by the lower target band used in 
STAR-Liège compared to the Standard protocol (4.4-8.0 
mmol/L vs. 5.6-8.3 mmol/L). Moreover, what characterises 
STAR is its power to determine SI based on clinical data and 
dynamically adjust treatment according to predicted SI 
variability, whereas nurses rely on clinical judgement. Hence, 
these insulin adjustments rates were commonly lower than 
recommended because of a fear of hypoglycaemia, especially 
in normoglycaemic ranges, resulting in higher %BG > 8.0 
mmol/L for little to no avoidance of hypoglycaemia (Table 
1). Additionally, the longest available treatment option 
suggested by STAR-Liège was not chosen 14% of the time, 
either by nurse choice or for clinical reasons, inducing 
additional workload, but potentially leading to slightly safer 
control. 
Per-patient time in band is consistently high, with the 
exception of one 1 patient (red trace in Figure 2). This patient 
was very resistant to insulin (median SI of 1.8e-4 L/mU/min), 
and rapidly fed with a consistent 8.4 g/h of total 
carbohydrates rate. STAR-Liège was thus recommending the 
maximum insulin rate possible, but could not effectively 
lower BG. In the second phase of the clinical trial, STAR-
Liège will also be allowed to modulate nutrition, and this is 
typically a case where nutrition would be decreased to lower 
BG to safer ranges.  
One BG < 4.0 mmol/L was measured and can also be seen 
Figure 2 (blue trace). This mild hypoglycaemic episode 
happened while no recorded insulin was administered to the 
patient during the previous two hours of treatment. It is hard 
to explain what might have happened, as this patient was 
receiving consistent 4.2 g/h of enteral carbohydrates. One 
explanation could be some undesired administered remaining 
insulin in the catheter, or wrong rate adjustment on the 
insulin pump. 
In this analysis, virtual trials of STAR-Liège and the 
Standard protocols using virtual patients created with the 
clinical data of the first 8 real patients are also used. Results 
show tighter control with lower and less variable BG 
outcomes for the STAR-Liège protocol, while ensuring 




     
 
similar very good safety. These results were achieved with 
modestly higher workload for the STAR-Liège protocol, 
showing this trade-off in GC. Retrospective data from 20 
patients controlled using the standard protocol supports the 
simulations trend of higher (expected) BG outcomes, but lack 
of compliance to this protocol was shown in clinical practice, 
questioning its potential improved outcomes.  
No matter the optimal target band chosen for GC, safety and 
performance must both be achieved for all patients, and 
repeatable across different ICU practices. STAR, and its 
unique risk-based dosing approach accounting for inter- and 
intra- patient variability, allow tighter control to a lower 
target band while ensuring both performance and safety. If 
some patients are “easy” to control, the “hard” patients to 
control are probably the ones that matter most. STAR-Liège, 
in line with previous results of the STAR GC framework, 
shows good control for essentially all patients, with very low 
episodes of hypoglycaemia. Most importantly, these results 
suggest the STAR framework generalises well to different 
population of critically ill patients, having potentially 
different underlying metabolic and ethnic conditions, and 
different ICUs across the world, as well as showing equal 
safety and performance using insulin-only control. 
 
5. CONCLUSIONS 
These preliminary results of the STAR-Liège clinical trial 
currently running at the University Hospital of Liège, 
Belgium, show positive GC outcomes from this GC protocol. 
The % BG time in target band is 78% with only 2% of mild 
hypoglycaemia and no severe hypoglycaemia. Compliance to 
the protocol is quite high, with only 14% of insulin 
intervention changed from the original recommendation. In-
silico trials show slightly higher performance and similar 
safety for the STAR-Liège protocol, reflecting what would 
likely have happened if nurse had exactly followed the 
protocol requirements. Compared to simulation results of the 
Standard protocol used in this ICU, STAR-Liège has lower 
and less variable BG outcomes while performing similar 
safety with increased workload. 
These results suggest these preliminary results of the STAR-
Liège trial are encouraging and support the continuation of 
this clinical trial.  
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